Tyrosine kinase inhibitors of EGF receptor (EGFR TKI) have dramatically changed the therapeutic paradigm of NSCLC [3], which are generated to bind and inhibit the intracellular kinase domain of EGFR with positive EGFR mutations [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.